Bioton SA of Poland estimates the
value of a distribution deal with GlaxoSmithKline Plc at as much
as $600 million, Puls Biznesu reported, citing Bioton Chief
Executive Officer Slawomir Ziegert.
Bioton announced the 15-year agreement, under which the
U.K.-based company will distribute the Polish producer’s insulin
in Russia, in a regulatory statement on Dec. 18.
To contact the reporter on this story:
Pawel Kozlowski in Warsaw
To contact the editor responsible for this story:
Gavin Serkin at
Press spacebar to pause and continue. Press esc to stop.